[News in gastrointestinal radiotherapy: The esophageal cancer].
Actualités en radiothérapie digestive : le cancer de l’œsophage.
Cancer
Esophagus
Radiotherapy
Radiothérapie
Œsophage
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
29
05
2022
revised:
09
06
2022
accepted:
14
06
2022
pubmed:
9
8
2022
medline:
21
9
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
Esophageal cancers continue to have a poor prognosis, even if this has improved over the past 25 years due to better management. Pre-operative chemotherapy with Paclitaxel-Carboplatin followed by adjuvant immunotherapy with Nivolumab represents a major advance in the management of locally advanced oesophageal cancer. Pre-operatively, chemo-radiotherapy can be performed in combination with FOLFOX or Paclitaxel-Carboplatin. Several trials are currently ongoing to evaluate the benefit of immunotherapy in non-operable cancers. In contrast, dose escalation in locally advanced non-operable tumors and the combination of pre-operative chemo-radiotherapy with trastuzumab have not been shown to be beneficial.
Identifiants
pubmed: 35941048
pii: S1278-3218(22)00112-3
doi: 10.1016/j.canrad.2022.06.004
pii:
doi:
Substances chimiques
Nivolumab
31YO63LBSN
Carboplatin
BG3F62OND5
Trastuzumab
P188ANX8CK
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
875-878Informations de copyright
Copyright © 2022 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.